No difference in safety for HIV+ pregnant women deferring TB Tx

. . . Compared with women who deferred INH therapy until 12 weeks postpartum, there was no significant difference in the incidence of any maternal grade 3 or 4 safety events, all cause hepatoxicity, or chemically caused liver damage, or infant grade 3 or 4 adverse events between groups, reported Amita Gupta, MD, of Johns Hopkins University in Baltimore, and colleagues.

At a press conference at the Conference on Retroviruses and Opportunistic Infections, Gupta said that tuberculosis (TB) peaks in women of reproductive age and when it develops during pregnancy, it has "negative sequelae for both mom and baby -- identifying a method to prevent TB during pregnancy and the postpartum period is an important way to address maternal-child health for a globally important disease such as tuberculosis." . . .